Previous 10 | Next 10 |
4 Penny Stocks To Watch For March 2020 Whether you’re a pro or novice, penny stocks have a place in the market for all traders. These speculative, low priced stocks have captivated the attention of investors for their ability to produce quick gains. This week the spotlight shined brig...
The FDA has granted Fast Track status to Pulmatrix's ( PULM +2.7% ) inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis in asthma patients. More news on: Pulmatrix, Inc., Healthcare stocks news, Stocks on the move, Read more ...
LEXINGTON, Mass. , Jan. 30, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PUR1900 ("Pulmazole"), the Company's inhaled itraconazole antifungal candidate being de...
LEXINGTON, Mass. , Jan. 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The Nasdaq Stock Market LLC, stating that the Company has regained compliance with Nasdaq's mini...
aTyr Pharma (NASDAQ: LIFE ) +63% on Kyorin Pharma deal . More news on: aTyr Pharma, Inc., Town Sports International Holdings, Inc., Pulmatrix, Inc., Stocks on the move, Read more ...
LEXINGTON, Mass. , Jan. 6, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that it has entered into a research collaboration with Nocio...
Novan (NASDAQ: NOVN ) -73% on failed SB206 study. More news on: Novan, Inc., DPW Holdings, Inc., Landec Corporation, Stocks on the move, Read more ...
Thinly traded nano cap Pulmatrix (NASDAQ: PULM ) is up 49% premarket on robust volume in reaction to its license and development deal with Johnson & Johnson's (NYSE: JNJ ) Lung Cancer Initiative for a lineup of narrow-spectrum kinase inhibitors. More news on: Pulmatrix, I...
LEXINGTON, Mass. , Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a licensing and development agre...
Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...